Superspreading of Covid-19 by Covid-19 Superspreaders
Covid-19 is an infectious disease caused by the SAR-CoV-2 virus. Covid-19 has become a major public health problem worldwide since its first identification in December 2019. A Covid-19 superspreader is a SAR-CoV-2-infected individual who transmits the virus to a large number of people, an event known as superspreading. Covid-19 superspreading usually occurs when a large group of people wearing no masks gather in indoor spaces with poor ventilation for a prolonged period of time. By using backward contract tracing to identify the Covid-19 superspreader and interrupting superspreading events, it would be possible to significantly reduce viral transmission and slow the Covid-19 outbreak.
2. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7:11.
3. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536–44.
4. Department of Disease Control, Ministry of Public Health. Corona Virus Disease (COVID-19) [Internet]. 22 February 2021 [cited 13 March 2021]. Available from: https://ddc.moph.go.th/viralpneumonia/index.php
5. De P, Chakraborty I, Karna B, Mazumder N. Brief review on repurposed drugs and vaccines for possible treatment of COVID-19. Eur J Pharmacol. 2021;898:173977.
6. Zuo YY, Uspal WE, Wei T. Airborne transmission of COVID-19: aerosol dispersion, lung deposition, and virus-receptor interactions. ACS Nano. 2020;14:16502–24.
7. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21:73–82.
8. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514-23.
9. Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Environ Res. 2020;188: 109819.
10. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382:1564-7.
11. Arslan M, Xu B, Gamal El-Din M. Transmission of SARS-CoV-2 via fecal-oral and aerosols-borne routes: environmental dynamics and implications for wastewater management in underprivileged societies. Sci Total Environ. 2020; 743:140709-15.
12. Wong DKC, Gendeh HS, Thong HK, Lum SG, Gendeh BS, Saim A, et al. A review of smell and taste dysfunction in COVID-19 patients. Med J Malaysia. 2020;75:574-81.
13. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141-54.
14. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6:28.
15. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412-23.
16. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383:1813-26.
17. Bo Y, Guo C, Lin C, Zeng Y, Li HB, Zhang Y, et al. Effectiveness of non-pharmaceutical interventions on COVID-19 transmission in 190 countries from 23 January to 13 April 2020. Int J Infect Dis. 2021;102:247-53
18. Ueki H, Furusawa Y, Iwatsuki-Horimoto K, Imai M, Kabata H, Nishimura H, et al. Effectiveness of face masks in preventing airborne transmission of SARS-CoV-2. mSphere. 2020;5:e00637-20.
19. Araghi F, Tabary M, Gheisari M, Abdollahimajd F, Dadkhahfar S. Hand hygiene among health care workers during COVID-19 pandemic: challenges and recommendations. Dermatitis. 2020; 31:233-7.
20. Stein RA. Super-spreaders in infectious diseases. Int J Infect Dis. 2011;15:e510-3.
21. Marineli F, Tsoucalas G, Karamanou M, Androutsos G. Mary Mallon (1869-1938) and the history of typhoid fever. Ann Gastroenterol. 2013;26:132-4.
22. Shen Z, Ning F, Zhou W, He X, Lin C, Chin DP, et al. Superspreading SARS events, Beijing, 2003. Emerg Infect Dis. 2004;10:256-60.
23. Yusef D, Hayajneh W, Awad S, Momany S, Khassawneh B, Samrah S, et al. Large outbreak of coronavirus disease among wedding attendees, Jordan. Emerg Infect Dis. 2020;26:2165-7.
24. Lemieux JE, Siddle KJ, Shaw BM, Loreth C, Schaffner SF, Gladden-Young A, et al. Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events. Science. 2021;371:eabe3261.
25. Hamner L, Dubbel P, Capron I, Ross A, Jordan A, Lee J, et al. High SARS-CoV-2 attack rate following exposure at a choir practice - Skagit County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69:606-10.
26. Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity of COVID-19 in South Korea. Int J Infect Dis. 2020;93:339-44.
27. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382: 970-1.
28. Majra D, Benson J, Pitts J, Stebbing J. SARS-CoV-2 (COVID-19) superspreader events. J Infect. 2021;82:36-40.
29. Rodríguez DJ, Torres-Sorando L. Models of infectious diseases in spatially heterogeneous environments. Bull Math Biol. 2001;63:547-71.
30. Delamater PL, Street EJ, Leslie TF, Yang YT, Jacobsen KH. Complexity of the basic reproduction number (R0). Emerg Infect Dis. 2019;25: 1-4.
31. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26: 729-34.
32. Adam DC, Wu P, Wong JY, Lau EHY, Tsang TK, Cauchemez S, et al. Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. Nat Med. 2020;26:1714–9.
33. Tellier R, Li Y, Cowling BJ, Tang JW. Recognition of aerosol transmission of infectious agents: a commentary. BMC Infect Dis. 2019;19:101.
34. Correia G, Rodrigues L, Gameiro da Silva M, Gonçalves T. Airborne route and bad use of ventilation systems as non-negligible factors in SARS-CoV-2 transmission. Med Hypotheses. 2020;141:109781.
35. Thomas RJ. Particle size and pathogenicity in the respiratory tract. Virulence. 2013;4:847-58.
36. Ryan BJ, Coppola D, Williams J, Swienton R. COVID-19 contact tracing solutions for mass gatherings. Disaster Med Public Health Prep. 2020:1-7.
37. Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH 3rd, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020;370:1464-8.
38. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021:eabg3055.
39. Furuse Y, Sando E, Tsuchiya N, Miyahara R, Yasuda I, Ko YK, et al. Clusters of coronavirus disease in communities, Japan, January–April 2020. Emerg Infect Dis. 2020;26:2176-9.
40. Kucharski AJ, Klepac P, Conlan AJK, Kissler SM, Tang ML, Fry H, et al. Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study. Lancet Infect Dis. 2020;20:1151-60.